I conduct research within the field of regulatory toxicology. My principal aim is to contribute to national and international efforts to improve regulatory risk assessment of endocrine disrupting compounds (EDCs).
There is a global concern that EDCs may be contributing to observed increases in endocrine-related disease in the human population, as well as effects in the environment. However, risk assessment of EDCs has proven complicated and is often hampered by large scientific uncertainties. One primary reason is the complex toxicity exhibited by hormonally active substances, which challenges the methods, assumptions and principles traditionally applied in toxicity testing and risk assessment. My work focuses on how these uncertainties can be reduced or handled. I am especially interested in how methods for evaluating reliability and relevance of data for risk assessment, as well as for conducting weight of evidence evaluations, can be developed and improved. Literature studies that scrutinize risk assessments and scientific literature, as well as relevant legislation and other policy documents, provide the basis for my research.
Latest scientific papers
Reliability and relevance evaluations of REACH data
Improving structure and transparency in reliability evaluations of data under REACH: suggestions for a systematic method
Toxicity studies used in REACH ‐ How accurately are they reported?
A call for action: Improve reporting of research studies to increase the scientific basis for regulatory decision‐making